BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome’s Interim Chief Financial Officer since January 2024.
“Max has been instrumental in Immunome’s rapid transformation over the last year, driving execution of major initiatives including our merger with Morphimmune, our strategic transactions with Zentalis and Ayala, and two financings totaling over $350 million,” said Clay Siegall, PhD, President and Chief Executive Officer. “Max’s strategic insight, financial acumen, and collaborative approach make him the right Chief Financial Officer for Immunome as we advance the Phase 3 RINGSIDE trial of AL102 in desmoid tumors, prepare IM-1021 and IM-3050 for IND submission, and seek to further expand our pipeline.”
“I am honored to take on the role of Chief Financial Officer, working alongside exceptional colleagues at a dynamic company,” said Mr. Rosett. “Immunome’s broad pipeline and compelling technology platforms present many opportunities to develop differentiated oncology therapies, and I look forward to advancing our mission of improving the lives of cancer patients.”
Max previously served in roles of increasing responsibility at Morphimmune, concluding as Acting Chief Operating Officer, and joined Immunome in October 2023 at the close of Morphimmune’s merger with Immunome. Prior to Morphimmune, Mr. Rosett was a Principal at Research Bridge Partners, a life science investment firm. He has also worked as a software engineer at Google, and he started his career at the Boston Consulting Group, where he served clients in the pharmaceutical industry. Mr. Rosett earned a M.S. in Computer Science from Georgia Institute of Technology and a B.A. in Mathematics from Yale University.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including small molecules, ADCs, RLTs and immunotherapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.
